drugset / Trial / NCT05900921
Trilaciclib Prior to Chemotherapy Plus Tislelizumab as 1L Treatment for Advanced Squamous Non-Small-Cell Lung Cancer
Phase 2
Unknown
132 enrolled
Sichuan University
Chengdu First People's Hospital · collabChengdu Second people's hospital · collabChengdu Seventh People's Hospital · collabEnshi Central Hospital · collabHeilongjiang Provicial Hospital · collabMianyang Central Hospital · collabNeijiang Hospital of Traditional Chinese Medicine · collabShandong Cancer Hospital and Institute · collabShanxi Province Cancer Hospital · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to explore the myeloprotective effects of trilaciclib in advanced squamous non-small cell lung cancer patients receiving a combination therapy of chemotherapy(carboplatin+paclitaxel) and immune checkpoint inhibitor (tislelizumab), as well as enhancing antitumor efficacy and possible immunological synergies.
Timeline
- Start
- 2023-07-01
- Primary completion
- 2024-10-31
- Completion
- 2025-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Trilaciclib | Unknown | 240 mg/m2 | Intravenous |
| Background | Carboplatin | Small molecule | — | Intravenous |
| Background | Paclitaxel | Small molecule | 175 mg/m2 | Intravenous |
| Background | Tislelizumab | Monoclonal antibody | 200 mg | Intravenous |